Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Medical Centre Groningen University Medical Center Nijmegen Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Vrije Universiteit Medical Center Leiden University Medical Center UMC Utrecht Erasmus Medical Center Maastricht University Medical Center Isala Klinieken Alysis Zorggroep St. Antonius Hospital Meander Medical Center Haga Hospital, Leyweg |
---|---|
Information provided by: | University Medical Centre Groningen |
ClinicalTrials.gov Identifier: | NCT00893555 |
The objective of this study proposal is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient outcomes (efficacy and safety) and is more cost-effective compared to the current standard of care.
Condition | Intervention | Phase |
---|---|---|
Invasive Fungal Infection Hematological Malignancy |
Drug: voriconazole (serum concentration based dosing) Drug: voriconazole (dosing according to the product information leaflet) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Pharmacologic Optimization of Voriconazole - a Prospective Clustered Group-Randomized Cross-Over Trial of Therapeutic Drug Monitoring |
Estimated Enrollment: | 200 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | April 2012 |
Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
control: Active Comparator
Voriconazole dosing based on product information leaflet
|
Drug: voriconazole (dosing according to the product information leaflet)
No serum concentrations are determined
|
TDM: Experimental
Voriconazole serum concentration based dosing
|
Drug: voriconazole (serum concentration based dosing)
Blood samples are drawn twice a week during voriconazole treatment. Voriconazole dosage is adapted to achieve serum trough concentrations of 2-5mg/L.
|
Patients with haematological malignancies and chemotherapy-induced prolonged neutropenia are at risk for severe bacterial and fungal infections. These opportunistic infections can result in prolonged hospital stay, increases costs and greater mortality. Voriconazole has now been recommended as the first line agent for invasive pulmonary aspergillosis. Retrospective observational studies of voriconazole serum concentration suggest that serum concentration correlate with toxicity and clinical response. These observations were however made in small series of patients and data were collected retrospectively.
These inherent methodological flaws make it impossible to draw definite conclusions about the effect of voriconazole serum level monitoring on the outcome of IA, and therefore considered insufficient proof to recommend voriconazole concentration determination in blood as standard of care. The impact that so called serum concentration guided dosing of voriconazole will have on treatment success can only be evaluated through a prospective randomized clinical trial.
For this purpose, we designed a prospective stratified cluster randomized cross-over trial of therapeutic drug monitoring in patients with haematological disease who have developed IA. The order of periods (TDM or standard of care, each 12 months) will be randomized per centre. During the TDM episode, the voriconazole dosage will be adjusted to achieve trough blood concentrations in a predefined window of 2-5 mg/L. A sample size of n=192 is needed to detect a 20% absolute reduction in the number of treatment failures (40% to 20 %) compared to control.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Netherlands | |
University Medical Center Groningen | Recruiting |
Groningen, Netherlands, 9713GZ | |
Contact: J WC Alffenaar, PharmD +31-50-3616161 | |
Principal Investigator: S MG Daenen, MD PhD |
Study Chair: | J GW Kosterink, PharmD, PhD | University Medical Centre Groningen |
Principal Investigator: | J WC Alffenaar, PharmD | University Medical Centre Groningen |
Responsible Party: | University Medical Center Groningen ( JGW Kosterink ) |
Study ID Numbers: | VORI911 |
Study First Received: | May 4, 2009 |
Last Updated: | May 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00893555 History of Changes |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Invasive fungal infection hematological malignancy voriconazole therapeutic drug monitoring |
Mycoses Hematologic Neoplasms Clotrimazole Hematologic Diseases |
Miconazole Antifungal Agents Voriconazole Tioconazole |
Anti-Infective Agents Mycoses Neoplasms Neoplasms by Site Hematologic Neoplasms Hematologic Diseases |
Therapeutic Uses Antifungal Agents Voriconazole Infection Pharmacologic Actions |